President and Chief Executive Officer
Jigar Raythatha has spent nearly 20 years in the biotechnology industry in a variety of business functions. He rejoined Constellation in May 2017 as the company’s chief executive officer from Jounce Therapeutics, where he held the role of chief business officer. At Jounce, Jigar was the first employee and helped build the company from its inception to a 100-person, publicly traded research and development organization. Previously, he served as head of corporate development at Constellation, where he led business development, strategy and program and alliance management functions. Prior to Constellation, Jigar worked with Red Abbey Venture Partners, evaluating from a Kauffman fellow, to principal and finally a venture partner. Earlier in his career, Jigar held roles of increasing responsibility at Biogen and A.T. Kearney. He earned a MBA Columbia University and a B.A. in biochemistry and economics from Rutgers University.
Chief Financial Officer
Emma Reeve is a global finance executive who has worked in healthcare for over 20 years across pharmaceutical, medical device and bio-pharma companies. Prior to joining Constellation Pharmaceuticals, Emma served as interim chief financial officer and corporate controller of PAREXEL International, where she was responsible for all aspects of financial reporting and accounting, investor relations, financial planning and analysis. Previously, Emma held senior finance roles at major pharma companies including Novartis, Merck and Bristol-Myers Squibb. She was also the chief financial officer of two development-stage biotech companies, Inotek Pharmaceuticals and Aton Pharma. In addition to finance, Emma has held senior positions in a number of countries in areas such as marketing, supply chain management and research operations. Emma holds a B.Sc. in computer science from Imperial College, University of London and is an associate of the Institute of Chartered Accountants in England & Wales.
Adrian Senderowicz, M.D.
Senior Vice President and Chief Medical Officer
Serving as Constellation Pharmaceuticals’ senior vice president and chief medical officer, Dr. Adrian Senderowicz is a board-certified medical oncologist with more than two decades of experience in the life sciences. As the principal investigator for a multitude of clinical trials in solid and hematological tumors, Adrian has significant regulatory expertise, including acting as a former clinical team leader at the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) Division of Drug Oncology Products. Prior to joining Constellation, Adrian served as chief medical officer at Cerulean Pharma, where he helped secure fast-track designation for the company’s lead clinical development program in two indications. Previously, Adrian held roles of increasing responsibility at Ignyta, Inc., Sanofi Oncology, Tokai Pharmaceuticals and AstraZeneca plc. He began his career as an investigator at the National Cancer Institute before joining the FDA’s CDER. Adrian completed his Internal Medicine residency training at the Icahn School of Medicine at Mount Sinai and a Clinical Oncology Fellowship at the NCI. He holds an M.D. degree from the School of Medicine at the Universidad de Buenos Aires in Argentina.
Senior Vice President, Corporate Development
Brad Prosek, Constellation Pharmaceutical’s senior vice president, corporate development, joined the company in 2017 from All Terrain bioPartners LLC, where he advised and supported a global set of life sciences clients on transaction, corporate and commercial strategy as well as execution. Previously, Brad spent 10 years at Cubist Pharmaceuticals, where he built the company’s market access strategy and organization, led transaction teams responsible for deals, including the acquisition of Trius Therapeutics, supporting the company’s pipeline growth and led a new corporate venture building a complementary infection prevention business. Prior to Cubist, Mr. Prosek served in growing commercial operations and market / business development roles at Biogen, and worked as a health economics and reimbursement strategy consultant with Covance in the United States and Europe.
Robert Sims, PhD
Senior Vice President of Research
Dr. Robert Sims, Constellation Pharmaceuticals’ senior vice president of research, joined the team in 2008 as a founding scientist. With nearly 20 years of experience in chromatin biology and transcription, Robert helped establish Constellation’s industry-leading epigenetics platform. Robert led the discovery and translational efforts for CPI-0610, a novel BET bromodomain inhibitor currently in Phase 1 clinical development for hematologic malignancies. His team’s notable work, along with others in the field, includes the discovery that BET bromodomain inhibition silences the expression of the MYC oncogene. Robert has authored more than 30 scientific publications in top-tier journals, including Science, Nature, and Cell. He received his Ph.D. in cellular and molecular biology from the University of Texas at Austin and completed his postdoctoral training at UMDNJ-Robert Wood Johnson Medical School and the New York University School of Medicine.
Brenda J. Sousa
Senior Vice President of Human Resources and Operations
Brenda Sousa is Constellation Pharmaceuticals’ senior vice president of human resources and operations. Prior to joining Constellation in 2010, Brenda was the vice president of human resources and operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for U.S. companies with international offices. Before joining EPIX, she was director of human resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare. Prior to her human resources career, Brenda worked in the hospitality industry focusing on sales and marketing. Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board. Brenda holds a B.A. from the University of Massachusetts.
Patrick Trojer, PhD
Senior Vice President, EZH2 Franchise and Head of Translational Sciences
Dr. Patrick Trojer joined Constellation Pharmaceuticals as a founding scientist in 2008 and currently serves as senior vice president, EZH2 franchise and head of translational sciences. Patrick has held multiple positions of increasing responsibility at Constellation, and among his many achievements, drove Constellation’s EZH2 program leading to the clinical launch of CPI-1205, which is currently in Phase 1 clinical trials for Lymphoma. Patrick is internationally recognized for his expertise in chromatin biology and its control of gene transcription, has authored dozens of scientific publications and is a frequent lecturer in the epigenetics space. Patrick completed his postdoctoral studies at NYU Medical School in Dr. Danny Reinberg’s laboratory, prior to which he received both a Ph.D. in protein biochemistry and molecular biology and M.S. in microbiology from the Leopold Franzens University in Innsbruck, Austria.
Board of Directors
Mark A. Goldsmith, M.D., Ph.D., Chairman
Founding President, CEO and Director, Revolution Medicines
Previously, Partner with Third Rock Ventures in its West Coast office. Prior to this, Dr. Goldsmith served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies.
James E. Audia, Ph.D.
Executive Director of the Chicago Biomedical Consortium
Dr. Jim Audia currently serves as Executive Director of the Chicago Biomedical Consortium, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation in the greater Chicago area. He joined the CBC after a nearly seven-year tenure as Constellation Pharmaceuticals’ chief scientific officer, where he oversaw the successful evolution of the company’s R&D efforts from a strong scientific base to a robust portfolio of clinical-stage assets and pre-clinical programs. Dr. Audia had joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. He held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 17 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 100 issued U.S. patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly. Dr. Audia currently serves as a scientific advisor for Sage Therapeutics, Ribon Therapeutics, and the Tau Consortium of the Rainwater Foundation.
Anthony Evnin, Ph.D.
Dr. Evnin is a Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He currently serves on the boards of AVEO Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc., and Pharmos Corporation as well as a number of private companies. Dr. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, and a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Dr. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.
Managing Partner and Founder, The Column Group
Peter has 30 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helped found companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Immune Design, and Gritstone and has served on the Boards of several other biotechnology companies, including Seragon Pharmaceuticals (Chairman), Aragon Pharmaceuticals (Chairman), Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.
Robert Tepper, M.D.
Partner, Third Rock Ventures
Dr. Tepper co-founded Third Rock Ventures in 2007 and serves as a Partner. Dr. Tepper works actively with portfolio companies to shape their scientific strategy. In this capacity Dr. Tepper worked as CSO of Constellation from April 2008 to October 2009. Prior to joining Third Rock Ventures, Dr. Tepper was President of R&D at Millennium Pharmaceuticals and co-founder of Cell Genesys/Abgenix. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, Tufts Medical School, and a member of the Research Advisory Council of Massachusetts General Hospital.
Constellation’s founders and scientific advisors are pioneers, authorities and thought leaders within the fields of epigenetics, drug discovery, and clinical medicine. They have made innumerable contributions to our understanding of epigenetic biology and to the development of novel therapeutics.
Danny Reinberg, Ph.D.
Terry and Mel Karmazin Professor, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine
Howard Hughes Medical Institute Investigator
Member of the National Academy of Sciences
David Allis, Ph.D.
Joy and Jack Fishman Professor and Head of the Laboratory of Chromatin Biology and Epigenetics at The Rockefeller University
Member of the National Academy of Sciences
Yang Shi, Ph.D
Professor of Cell Biology, HMS and Merton Bernfield Professor of Neonatology at Children’s Hospital
Scientific Advisory Board
David Livingston, M.D.
Deputy Director, Dana Farber Harvard Cancer Center
Professor of Medicine and Genetics, Harvard Medical School
Scott Lowe, Ph.D.
Chair of the Geoffrey Beene Cancer Research Center
Cancer Biology and Genetics Program, Sloan-Kettering Institute
Howard Hughes Medical Institute
Robert Schreiber, Ph.D.
Alumni Endowed Professor of Pathology and Immunology
Professor of Molecular Microbiology
Director of the Center for Human Immunology and Immunotherapy programs, Washington University School of Medicine
Padmanee Sharma, M.D., Ph.D.
Professor, Department of Genitourinary Medical Oncology, Department of Immunology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX